Sy Mukherjee

Sy Mukherjee is a former health care reporter for Fortune.

Page 64 of 100

  • Health

    Brainstorm Health: New Zealand’s HIV Prevention Plan, Apple Watch Diabetes Study, FDA Vs Kratom

    By
  • Celebrities At The Los Angeles Lakers GameHealth

    America’s Richest and Most Controversial Doctor Is Buying the ‘Los Angeles Times’

    By
  • The psychiatric unit of a hospital in Haute Savoie, FranceHealth

    The Diseases We Aren’t Curing—And Why

    By
  • Philadelphia lost its mind following a Super Bowl win.Health

    Psychologists Explain Why Some Eagles Fans Rioted After Winning the Super Bowl

    By
  • Health

    Brainstorm Health: The Science of Super Bowl Riots, Intarcia Setback, Sanofi Dengue Lawsuit

    By
  • Children vaccinate vaccine prevent fluHealth

    53 Children Have Now Died During This Year’s Flu Season—and It Could Get Even Worse

    By
  • Macro of oxycodone opioid tabletsHealth

    How Bad Is the Opioid Crisis? People Are Abusing Anti-Diarrhea Medicine to Keep Their Highs

    By
  • President Trump Delivers His First State Of The Union AddressHealth

    Trump Called for a ‘Right to Try’ Law During His State of the Union. Here’s What That Means

    By
  • Health

    Brainstorm Health: Right to Try, Alzheimer’s Blood Test, Vertex Cystic Fibrosis Trials

    By
  • Amazon logoHealth

    It’s Too Early for Investors to Freak Out About Amazon Disrupting Health Care

    By
  • Health

    Brainstorm Health: Amazon’s Health Care Announcement, Pfizer Tax Gain, Telehealth and Medicare

    By
  • A Pfizer sign hangs on the outside of their headquarters in New York City.Health

    Pfizer Is the Latest Drug Maker to Reap Billions From Trump’s Tax Cuts

    By
  • Drug users inject a mixture of heroin and water at a drug den in Ciudad JuarezHealth

    Philadelphia Has a Controversial Plan for Fighting the Opioid Crisis: ‘Safe Injection Sites’

    By
  • Health

    Brainstorm Health: Apple Health Records, Safe Injection Sites, Novartis Earnings

    By
  • Inside The Nasdaq MarketSite As Juno Therapeutics Releases IPOHealth

    Why Analysts Are Calling Celgene’s $9 Billion Juno Acquisition a ‘Smart’ Biotech Deal

    By